We provide evidence that the anti-tumor efficacy of doxorubicin is enhanced by combination therapy with the MEK inhibitor trametinib, which strengthens GSK3β activity, thus blocking oncogenic signaling. This evidence concerns the gene GSK3B and neoplasm.